Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Organon & Co. Common Stock (NY:OGN)

6.780 -0.210 (-3.00%)
Streaming Delayed Price Updated: 1:44 PM EST, Dec 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Organon & Co. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
3 Healthcare Stocks with Questionable Fundamentals
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have... 
Via StockStory
Topics Stocks
News headline image
Why Organon (OGN) Shares Are Trading Lower Today
Shares of pharmaceutical company Organon (NYSE:OGN) fell 4.7% in the afternoon session after Barclays initiated coverage on the company with an 'Underweight' rating and a price target of $7.50. The new... 
Via StockStory
Topics Initial Public Offering
News headline image
3 Stocks Under $10 We Steer Clear Of
Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn’t mean they’re bargains though, and we urge investors to be... 
Via StockStory
News headline image
Earnings Scheduled For November 10, 2025 ↗
 
Via Benzinga
News headline image
A Look at Organon's Upcoming Earnings Report ↗
 
Via Benzinga
News headline image
3 Value Stocks with Questionable Fundamentals
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
News headline image
3 Cash-Producing Stocks We Find Risky
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
Organon (OGN): Buy, Sell, or Hold Post Q3 Earnings?
Over the past six months, Organon’s stock price fell to $7.77. Shareholders have lost 16.1% of their capital, which is disappointing considering the S&P 500 has climbed by 14.7%. This may have... 
Via StockStory
Topics Stocks
News headline image
Q3 Rundown: Organon (NYSE:OGN) Vs Other Branded Pharmaceuticals Stocks
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Organon (NYSE:OGN) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
The 5 Most Interesting Analyst Questions From Organon’s Q3 Earnings Call
Organon's third quarter was marked by better-than-expected top-line and bottom-line results, which were well received by the market. Management attributed the quarter’s outperformance to strong... 
Via StockStory
Topics Earnings
News headline image
Organon (OGN) Stock Trades Down, Here Is Why
Shares of pharmaceutical company Organon (NYSE:OGN) fell 2.9% in the afternoon session after the company lowered its full-year sales guidance and analysts subsequently cut their price targets on the... 
Via StockStory
Topics Artificial Intelligence Initial Public Offering Supply Chain
News headline image
Organon Analysts Cut Their Forecasts Following Q3 Results ↗
 
Via Benzinga
News headline image
OGN Q3 2025 Deep Dive: Leadership Changes, Portfolio Shifts, and Guidance Recalibration
Pharmaceutical company Organon (NYSE:OGN) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 1.3% year on year to $1.60 billion. On the other hand, the company’s... 
Via StockStory
News headline image
Tech Rallies, Palantir Jumps 6% As Shutdown End Looms: What's Moving Markets Monday? ↗
Wall Street rebounded on Monday, recovering part of last week's steep losses as investors grew more confident about risk assets amid encouraging signs from Washington that the record-long government... 
Via Benzinga
News headline image
Organon Cuts 2025 Sales Outlook Despite Earnings Beat ↗
Organon posts Q3 EPS of $1.01, topping estimates, trims 2025 sales outlook, and highlights positive Vtama data in children with atopic dermatitis. 
Via Benzinga
News headline image
Organon (NYSE:OGN) Posts Better-Than-Expected Sales In Q3
Pharmaceutical company Organon (NYSE:OGN) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 1.3% year on year to $1.60 billion. On the other hand, the company’s... 
Via StockStory
News headline image
Organon (OGN) Reports Earnings Tomorrow: What To Expect
Pharmaceutical company Organon (NYSE:OGN) will be announcing earnings results this Monday before market hours. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
News headline image
2 Safe-and-Steady Stocks with Impressive Fundamentals and 1 We Avoid
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
News headline image
1 of Wall Street’s Favorite Stock with Impressive Fundamentals and 2 We Ignore
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
News headline image
Why Organon (OGN) Stock Is Down Today
Shares of pharmaceutical company Organon (NYSE:OGN) fell 8.9% in the afternoon session after the company announced the resignation of CEO Kevin Ali after an internal investigation uncovered improper... 
Via StockStory
Topics Economy Government Initial Public Offering
News headline image
Which stocks are moving on Monday? ↗
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Keep an eye on the top gainers and losers in Monday's session. ↗
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Gold Falls 3%; Carter's Shares Gain After Q3 Earnings ↗
 
Via Benzinga
News headline image
Which stocks are gapping on Monday? ↗
The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
These stocks are moving in today's pre-market session ↗
Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
Organon CEO Kevin Ali Resigns Amid Audit Probe Into Wholesaler Sales Practices ↗
Organon said that the investigation found that certain wholesalers in the United States were asked to buy more Nexplanon than they needed. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
3 Small-Cap Stocks We Steer Clear Of
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
News headline image
1 Profitable Stock Worth Your Attention and 2 Facing Challenges
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.